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Background: Patient–physician communication is critical for help-
ing patients understand and complete the complex steps needed to 
diagnose stage and treat lung cancer. We assessed which domains 
of patient–physician communication about lung cancer and its treat-
ment are associated with receipt of disease-directed, stage-appropri-
ate treatment.
Methods: Patients with recently diagnosed lung cancer were 
recruited from four medical centers in New York City from 2008 
to 2011. Participants were surveyed about discussions with physi-
cians regarding treatment, symptoms, and needs. Multiple regression 
analysis and structural equation modeling were used to assess which 
communication factors were associated with disease treatment.
Results: Of the 352 participants, 191 (54%) received disease-directed, 
stage-appropriate treatment. Unadjusted associations between com-
munication items and treatment found that participants who felt that 
their physicians explained the risks and disadvantages of lung cancer 
treatment (p < 0.01), discussed their chances of cure (p = 0.02), dis-
cussed goals of treatment (p < 0.01), or who were warm and friendly 
(p = 0.04) were more likely to undergo treatment. Three commu-
nication domains were identified: treatment information, physician 
support, and patient symptoms/needs. After adjusting for known 
determinants of lung cancer treatment, increased treatment informa-
tion was associated with higher probability of cancer-directed treat-
ment (p = 0.003). Other communication domains (physician support 
or patient symptoms/needs) were not independent predictors of treat-
ment (p > 0.05 for both comparisons).
Conclusion: These data suggest that treatment information is par-
ticularly important for increasing the probability of cancer-directed 
therapy among lung cancer patients. Clinicians should ensure that 
they clearly discuss treatment goals and options with patients while 
maintaining empathy, supporting patient needs, and addressing 
symptoms.
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(J Thorac Oncol. 2014;9: 1249–1254)
Despite the high mortality rate and poor overall prognosis of lung cancer, appropriate treatment is associated with 
decreased morbidity and improved survival, particularly 
for patients with non-metastatic disease.1 Even for more 
advanced disease stages, chemotherapy along with support-
ive care can increase the median survival and improve qual-
ity of life.2 The process leading to lung cancer treatment, 
from initiation to completion, is quite involved. To receive 
cancer-directed therapy, lung cancer patients need to be 
diagnosed in a timely manner, appropriately staged, and then 
may need to undergo multipart treatment procedures such 
as surgery, chemotherapy, and/or radiation. Successful treat-
ment requires complex care coordination, effective manage-
ment, and ongoing communication with multiple providers. 
As a result, patients need a clear understanding of their dis-
ease and treatment options to be able to make decisions and 
initiate treatment.
Several factors such as access to care, the ability to 
navigate the complexities of the healthcare system, and social 
support can influence whether lung cancer patients receive 
treatment.3–5 In addition, patients’ understanding of diagnos-
tic tests, treatment options, and prognosis, coupled with their 
ability to adhere to provider recommendations, may affect 
whether patients ultimately accept and undergo treatment. 
Therefore, patient–physician communication likely plays 
a key role in ensuring that lung cancer patients understand 
the rationale and importance of treatment and complete these 
complex steps.
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Prior research has shown that while many patients with 
lung cancer are satisfied with how clinicians discuss diagno-
sis and treatment options, physicians’ communication about 
treatment goals remains suboptimal.6 Moreover, poor com-
munication resulting in unattended patient needs has been 
reported across all stages of lung cancer.7 However, the poten-
tial impact of patient–provider communication on lung cancer 
treatment has not been previously explored. In this study, we 
assessed which domains of patient–physician communication 
about lung cancer and its treatment are associated with receipt 
of stage-appropriate cancer-directed treatment.
PATIENTS AND METHODS
A cohort of lung cancer patients were recruited 
from four New York City hospitals (Mount Sinai Hospital, 
Montefiore Hospital, New York-Presbyterian Hospital and 
Harlem Hospital) between January 11, 2008, and November 
9, 2011. We identified potential participants using central-
ized registries maintained by the hospitals’ pathology depart-
ments and/or institutional tumor registries. To ensure we 
captured all potential study subjects, we also regularly con-
tacted lung cancer providers, conducted weekly screenings 
of oncology, radiotherapy, and pulmonary clinics, posted 
flyers advertising the study at treatment sites, and communi-
cated with clinicians serving on tumor boards of the partici-
pating hospitals.
Patients were eligible for the study if they were English 
or Spanish speaking, older than 18 years, and diagnosed with 
primary lung cancer within the previous 12 months. Potential 
participants were excluded if they were without decisional 
capacity or had been diagnosed with another malignancy 
(other than non-melanoma skin cancer) within the past 5 
years. Eligible patients were undergoing staging work-up 
or treatment when they were approached by the study team. 
Once participants signed informed consent, they underwent 
a standardized in-person baseline interview in their preferred 
language. Follow-up phone interviews were conducted to 
collect data on primary, cancer-directed treatment. Medical 
record review was conducted using a standardized instru-
ment to obtain and confirm information about patients’ diag-
nostic evaluation, cancer stage, and treatment. The study was 
approved by the Institutional Review Boards of all participat-
ing institutions.
Sociodemographic characteristics, including age, sex, 
race, ethnicity, marital status, primary language, educa-
tion, insurance status, and income were collected by patient 
self-report. Patients were classified according to the Tumor, 
Node, and Metastasis staging criteria of the American Joint 
Committee on Cancer (7th edition) through review of medi-
cal records, pathology reports, and tumor registry data. 
Information about comorbidities was collected by self-
report and confirmed by chart review. Performance status 
was assessed by patient report using the Eastern Cooperative 
Oncology Group (ECOG) instrument.8
Questions regarding physician communication cov-
ered several domains (Table 2). The first group of questions 
focused on lung cancer treatment and goals of care and 
included items inquiring if lung cancer doctors explained 
the disease itself; the benefits and disadvantages, potential 
complications and goals of treatment; and the chances of 
cure. The second domain focused on patients’ physical, 
emotional, spiritual and practical needs. Items inquired 
about whether doctors discussed emotional issues (sad-
ness, anxiety, etc.), physical symptoms, spiritual concerns, 
or practical needs (transportation to appointments, home-
making assistance). The third domain included items about 
physician support, such as whether their doctors encouraged 
patients to ask questions, used simple language, showed they 
care, and were warm and friendly. Questions were devel-
oped with input from an interdisciplinary team of experts 
in lung cancer, patient–physician communication, psychol-
ogy and palliative care; details about survey development 
have been previously described.7 Responses rated level of 
agreement with statements either on a 4-point Likert scale, 
ranging from “strongly agree” to “strongly disagree” or on 
a 5-point Likert scale from discussed “not at all,” “a little 
bit,” “somewhat,” “quite a bit,” or “a lot.” Reponses were 
dichotomized: strongly agree and agree were combined 
into one category versus disagree and strongly disagree and 
quite a bit and a lot were combined versus somewhat, a little 
bit, and not at all.
The study outcome, receipt of disease-directed, stage-
appropriate treatment (including surgery, chemotherapy, 
and/or radiation therapy), was defined based on the National 
Comprehensive Cancer Network (NCCN) recommendations 
for lung cancer management.9 Treatment was ascertained 
through medical chart review, and patients were classified 
as having received such treatment if they underwent NCCN-
concordant primary lung cancer-directed therapy within a year 
of diagnosis (see supplemental table, Supplemental Digital 
Content, http://links.lww.com/JTO/A639).
Statistical Analysis
We used descriptive statistics to summarize sociode-
mographic characteristics of participants. The unadjusted 
association between patient–physician communication items 
within each domain and receipt of cancer-directed, stage-
appropriate treatment was assessed using the χ2 or Fisher’s 
exact test, as appropriate. We used exploratory factor analy-
sis to identify latent factors representing different commu-
nication domains. Based on the scree plot and eigenvalues 
(values >1), we identified three latent factors. Items with 
absolute loadings greater than 0.5 and that were theoretically 
congruent with prior knowledge were assigned to specific 
factors. We then used structural equation modeling (SEM) 
to evaluate which communication factors were associated 
with receipt of stage-appropriate treatment. The SEM was 
adjusted for age, gender, race/ethnicity, primary language, 
marital status, income, insurance, comorbidities, lung can-
cer stage, and performance status. Effect estimates from the 
latent communication factors leading into treatment repre-
sent the increase in the probit of the likelihood of receiv-
ing treatment with a one standard deviation increase in the 
communication factor score. Model fit was assessed with the 
root mean square error of approximation and the compara-
tive fit index. Analyses were conducted with SAS9.2 (SAS 
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Institute Inc., Cary, NC) and Mplus7 (Muthen & Muthen, 
Los Angeles, CA).
RESULTS
During the study period, we screened 1542 patients, 
of whom 484 were eligible for and 368 (76%) were enrolled 
in the study. Cancer stage information was missing for 16 
patients who were excluded from the analysis, leaving a final 
cohort of 352 lung cancer patients.
Participants’ sociodemographic and lung cancer char-
acteristics are shown in Table 1. The mean (SD) age of par-
ticipants was 65.7 (11) years, 168 (48%) were men and 193 
(55%) were married. Twenty-one percent were black, 20% 
were Hispanic and 55% were white. Eighty percent of par-
ticipants were native English speakers and 75% had a high 
school or greater education. Overall, 191 (54%) of partici-
pants received disease-directed, stage-appropriate treatment.
Unadjusted Association of 
Communication and Treatment
The unadjusted associations between communication 
items and receipt of cancer-directed, stage-appropriate treat-
ment are shown in Table 2. Several items in the treatment 
and goals of care domain were associated with treatment 
rates. Participants who felt that their physicians explained to 
their satisfaction the risks and disadvantages of lung cancer 
treatment were more likely to undergo treatment (p < 0.01). 
Similarly, treatment was more frequent among those who 
reported that their doctors discussed their chances of cure 
(p = 0.02) and goals of treatment (p < 0.01). Other items in 
this domain were not associated with treatment rates (p > 0.05 
for all comparisons).
One item in the provider support domain was associated 
with cancer-directed, stage-appropriate treatment. Patients 
who felt that their doctors were warm and friendly were more 
likely to undergo treatment (p = 0.04). None of the items in 
the domain assessing communication about patient needs was 
associated with stage-appropriate treatment rates (p > 0.05 for 
all comparisons).
Exploratory Factor Analysis and 
Structural Equation Modeling
All items assessing patient–provider communica-
tion were entered into an exploratory factor analysis. Factor 
loadings are shown in Table 3. Based on factor loadings and 
theoretical considerations, the three communication factors 
selected for SEM were: (1) physician support (comprising 
TABLE 1.  Characteristics of the Study Participants (n = 352)a
Characteristic Value
Age, yr, mean ± SD 66 ± 11
Male, n (%) 168 (48)
Married, n (%) 193 (55)
Native English-speaking, n (%) 284 (81)
Race/ethnicity, n (%)
  White 181 (55)
  Black 68 (21)
  Hispanic 64 (20)
  Other 14 (4)
Education, n (%)
  Did not graduate high school 83 (25)
  High school graduate 146 (45)
  College graduate 98 (30)
Income, n (%)
  ≤$15,000 69 (20)
  $15,000–50,000 74 (21)
  ≥$50,000 72 (21)
  Refused/do not know 133 (38)
Insurance, n (%)
  Commercial 168 (51)
  Medicare 131 (39)
  Medicaid/none 34 (10)
TNM stage, n (%)
  IA 118 (34)
  IB 43 (12)
  IIA 11 (3)
  IIB 22 (6)
  IIIA 40 (11)
  IIIB 35 (10)
  IV/extensive 83 (24)
ECOG performance status: fully active, n (%) 173 (50)
Received stage-appropriate treatment, n (%) 191 (54)
a For some characteristics, totals are <352 due to missing responses.
ECOG, Eastern Cooperative Oncology Group; TNM, tumor, node, metastasis.
TABLE 2.  Unadjusted Associations between Patient–
Physician Communication and Receipt of Stage-Appropriate 
Cancer-Directed Treatment
Communication Items, n (%)
Treatment
p Value
Yes  
(n = 191)
No  
(n = 
161)
Treatment and goals of care
  Explained benefits and disadvantages of 
  treatments
173 (92) 125 (83) <0.01
  Talked about chances of curing cancer 126 (67) 82 (54) 0.02
  Explained what lung cancer is 166 (87) 141 (89) 0.59
  Discussed goals of treatment 152 (80) 99 (68) <0.01
  Discussed complications of treatment 134 (71) 101 (64) 0.22
Physician support
  Showed care about me 186 (98) 155 (98) 0.90a
  Warm and friendly 190 (100) 154 (97) 0.04a
  Used simple language 184 (97) 152 (96) 0.74a
  Encouraged asking questions 180 (95) 145 (93) 0.49
Patient needs
  Discussed emotional symptoms 88 (47) 69 (45) 0.79
  Discussed physical symptoms 148 (78) 113 (73) 0.24
  Discussed practical needs 60 (32) 50 (32) 0.92
  Discussed spiritual concerns 39 (21) 34 (22) 0.85
aFisher’s exact test.
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four items), (2) treatment information (comprising three 
items), and (3) patient symptoms and needs (comprising two 
items).
After adjusting for race/ethnicity, native language, 
marital status, income, insurance, comorbidities, lung cancer 
stage, and performance status, SEM showed that higher scores 
in the treatment information latent factor were associated with 
increased probability of receiving cancer-directed, stage-
appropriate treatment (estimate = 0.59, p = 0.004; Fig. 1). 
Conversely, the latent communication factors representing 
physician support (estimate = 0.11, p = 0.58) and patient 
symptoms/needs (estimate = −0.28, p = 0.07) were not sig-
nificantly associated with treatment. The model fit was good 
with a root mean square error of approximation = 0.023 and 
comparative fit index = 0.936.
DISCUSSION
Prior studies have shown that effective patient–physi-
cian communication improves patients’ knowledge and con-
trol over treatment decisions.10,11 We found that after adjusting 
for known determinants of treatment, better perceived com-
munication about lung cancer management and goals of care 
was associated with increased probability of cancer-directed, 
stage-appropriate treatment. Other communication domains 
such as physician support or discussions about patients’ symp-
toms/needs were not independently associated with treatment 
rates. Our findings emphasize the importance of physicians’ 
role in effectively explaining information about treatment 
goals and options to lung cancer patients while maintaining 
empathy.
The impact of a new lung cancer diagnosis, com-
pounded by the subsequent staging process and discussion of 
complex treatment recommendations, can be overwhelming 
for patients.12 Many patients fail to understand the prognosis 
and goals of their treatment, and most physicians are unaware 
of these misunderstandings.1 In addition, while patients with 
early-stage lung cancer can be cured by surgical resection, 
metastatic disease can be only ameliorated with chemother-
apy.13 Thus, for patients with advanced disease, physicians 
need to engage in potentially difficult discussions about goals 
of care and overall prognosis.2 Unfortunately, most patients do 
not receive enough information to make informed decisions,14 
a factor that may contribute to lack of appropriate treatment 
with consequent decreased survival and poorer quality of life.
While the literature shows that communication is related 
to treatment rates,15–17 which domains of communication are 
most important remains unclear. Cykert et al.17 showed that 
lower overall patient–physician communication scores were 
associated with decreased rates of surgery for lung cancer, 
but did not evaluate particular communication domains that 
were related to surgery rates or explore other treatment types. 
Accurately providing information about treatment benefits 
and risks and goals of treatment may increase the likeli-
hood that cancer patients undergo the complex steps needed 
to stage and treat their disease. In support, we found that the 
communication domain of providing information about treat-
ment options and goals was associated with receipt of cancer-
directed stage-appropriate treatment.
TABLE 3.  Exploratory Factor Analysis of Patient–Physician 
Communication Items
Communication Items
Factor Loadings
1 2 3
Providing information
  Explained benefits and disadvantages of 
  treatmentsa
0.123 −0.566 0.102
  Talked about chances of curing cancer 0.024 0.315 0.309
  Explained what lung cancer is 0.619 −0.316 −0.012
  Discussed goals of treatmenta 0.012 0.524 0.234
  Discussed complications of treatmenta −0.006 0.545 0.163
Physician support
  Showed they care about mea 0.946 0.004 −0.004
  Was warm and friendlya 0.966 0.023 0.036
  Used simple languagea 0.775 −0.135 −0.001
  Encouraged asking questionsa 0.765 −0.208 −0.001
Patient symptoms and needs
  Discussed emotional symptomsa 0.010 0.102 0.700
  Discussed physical symptoms −0.012 0.374 0.455
  Discussed practical needsa −0.008 0.000 0.733
  Discussed spiritual concerns −0.008 −0.173 0.792
a Items included in final structural equation modeling with latent communication 
factors.
FIGURE 1.  Structural equation 
model of communication factors and 
cancer-directed, stage-appropriate 
treatment. Model adjusted for age, 
gender, marital status, income, insur-
ance, native language, comorbidities, 
lung cancer stage, and performance 
status. *p value < 0.05.
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Studies have shown that effective communication is 
correlated with improved health outcomes, may reduce uncer-
tainty, and alleviate patient concerns about treatment.18–21 
Specifically, providing information about treatment side 
effects, extent of the disease, prognosis, and chances of cure 
can help meet patients’ informational needs.22,23 In addition, 
patient satisfaction is influenced by physicians’ ability to 
exhibit friendly and compassionate behavior,24 and a warm 
communication style is important in making patients feel 
comfortable asking questions.25 Prior studies have shown 
that empathic communication is important for reducing anxi-
ety and fear, providing support and reassurance, improving 
patient satisfaction, and adherence to physician recommen-
dations.26–29 However, we did not find that physician support 
was associated with increased cancer-directed treatment rates. 
This lack of association may have been due, in part, to the 
low variability in physician support items, as most patients 
in our cohort reported very high levels of physician empathic 
support. Certainly, a warm communication style is critical for 
establishing patient rapport and trust, and can help patients 
modulate their emotions so that they are able to absorb and 
process information about prognosis and weigh the benefits 
and burdens of treatment options. However, empathic commu-
nication itself may not be sufficient for ensuring that patients 
undergo treatment.
Consideration of patients’ symptoms, functioning, cop-
ing strategies, and social support is key in addressing these 
important needs that can substantially impact quality of life in 
lung cancer patients.30–32 Helping patients navigate a complex 
medical system, facilitating transportation to appointments, 
ensuring adequate social and/or emotional support can help 
patients adhere to treatment recommendations. However, we 
did not find that addressing patients’ symptoms or needs was 
associated with increased rates of treatment. Perhaps this was 
due to the low percentage of physicians who discussed practi-
cal, spiritual and emotional needs with patients. Alternatively, 
patients may have already been receiving support from fam-
ily, friends, social workers, or other non-physician members 
of the healthcare team. Physicians should nonetheless ensure 
that the healthcare team addresses these important issues, 
which have been associated improved treatment adherence in 
other chronic diseases and in cancer screening practices.33–35
There are some limitations to our study. Communication 
was measured through patient report, rather than by directly 
observing and/or recording of patient–physician conversa-
tions. However, given that most lung cancer patients interact 
with multiple different providers during their course of diag-
nosis, staging, and treatment, it would be difficult to directly 
observe all these encounters to assess patient–physician com-
munication. Thus, a self-reported measure may be more help-
ful capturing the overall communication process. Furthermore, 
patients’ perception of how their providers communicate 
often affects their medical decision-making behaviors.36,37 
Although we attempted to enroll patients early in the course 
of the disease (median time from diagnosis to enrollment was 
3 months), some patients may have been interviewed during 
their treatment course. Thus, we cannot establish a causal link 
between communication and treatment. We were also not able 
to assess whether some patients did not receive stage-appro-
priate therapy due to lack of physician recommendation and 
we did not take into account comorbidities or performance 
status when deciding whether or not a patient should have 
received adjuvant therapy but we did adjust for comorbidi-
ties and performance status in the analysis. We recruited lung 
cancer patients from a single urban area so our results may 
not be generalizable to other settings. However, we conducted 
the study at several sites that provide care to a large segment 
of the community. Our sample had an overrepresentation of 
patients with early-stage lung cancer, compared with national 
rates. However, communication processes should be impor-
tant regardless of disease stage and we controlled for stage 
in our adjusted analyses. Finally, our sample size may not 
have been sufficient to detect communication factors that had 
weaker associations with treatment. Future studies should aim 
to objectively assess communication before treatment deci-
sions to more firmly establish the relationship between com-
munication factors and receipt of cancer treatment.
In summary, we found that perceived communica-
tion about benefits, disadvantages and goals of treatment to 
lung cancer patients was associated with an increased rate of 
undergoing stage-appropriate, cancer-directed treatment. In 
contrast, we observed that physician support and communi-
cation about patients’ symptoms or needs, while important 
components of patient-centered care, were not associated with 
disease-directed treatment. Nevertheless, physician empathy 
remains critical to supporting patients during decision-making 
about and throughout cancer treatment. These data highlight 
the importance of ensuring that clear discussion about treat-
ment goals and options with lung cancer patients occur while 
maintaining empathy, supporting patient needs, and address-
ing symptoms. Future steps may include specific interventions 
to improve this important aspect of care.
ACKNOWLEDGMENTS
We thank Giselle Campos, BA, Amy S. Walker, MA, 
Andrea Maldonado, BA, and Liliana Serrano, BS, for their 
efforts recruiting and interviewing study subjects. We greatly 
appreciate the thoughtful and critical comments from Judith 
E. Nelson, MD, JD, in discussions about this manuscript.
REFERENCES
 1. Quirt CF, Mackillop WJ, Ginsburg AD, et al. Do doctors know when their 
patients don’t? A survey of doctor-patient communication in lung cancer. 
Lung Cancer 1997;18:1–20.
 2. Ihde DC. Drug-therapy—chemotherapy of lung-cancer. N Engl J Med 
1992;327:1434–1441.
 3. Greenberg ER, Chute CG, Stukel T, et al. Social and economic-factors in 
the choice of lung-cancer treatment. A population-based study in 2 rural 
states. N Engl J Med 1988;318:612–617.
 4. Groth SS, Al-Refaie WB, Zhong W, et al. Effect of insurance status on the 
surgical treatment of early-stage non-small cell lung cancer. Ann Thorac 
Surg 2013;95:1221–1226.
 5. Forrest LF, Adams J, Wareham H, Rubin G, White M. Socioeconomic 
inequalities in lung cancer treatment: systematic review and meta-analy-
sis. PLoS Med 2013;10:e1001376.
 6. Gabrijel S, Grize L, Helfenstein E, et al. Receiving the diagnosis of lung 
cancer: Patient recall of information and satisfaction with physician com-
munication. J Clin Oncol 2008;26:297–302.
1254 Copyright © 2014 by the International Association for the Study of Lung Cancer
Lin et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 9, September 2014
 7. Nelson JE, Gay EB, Berman AR, Powell CA, Salazar-Schicchi J, 
Wisnivesky JP. Patients rate physician communication about lung cancer. 
Cancer 2011;117:5212–5220.
 8. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response cri-
teria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 
1982;5:649–655.
 9. Underwood JM, Townsend JS, Tai E, et al. Racial and regional disparities 
in lung cancer incidence. Cancer 2012;118:1910–1918.
 10. Charles C, Gafni A, Whelan T. Shared decision-making in the medical 
encounter: what does it mean? (or it takes at least two to tango). Soc Sci 
Med 1997;44:681–692.
 11. Eddy DM. Clinical decision making: from theory to practice. Anatomy of 
a decision. JAMA 1990;263:441–443.
 12. Marbach TJ, Griffie J. Patient preferences concerning treatment plans, 
survivorship care plans, education, and support services. Oncol Nurs 
Forum 2011;38:335–342.
 13. Handy JR Jr. Functional outcomes after lung cancer resection: who cares 
as long as you are cured? Chest 2009;135:258–259. 
 14. Koedoot CG, Oort FJ, de Haan RJ, Bakker PJM, de Graeff A, de Haes 
J. The content and amount of information given by medical oncolo-
gists when telling patients with advanced cancer what their treatment 
options are: palliative chemotherapy and watchful-waiting. Eur J Cancer 
2004;40:225–235.
 15. Zolnierek KB, Dimatteo MR. Physician communication and patient 
adherence to treatment: a meta-analysis. Med Care 2009;47:826–834.
 16. Liang WH, Burnett CB, Rowland JH, et al. Communication between phy-
sicians and older women with localized breast cancer: Implications for 
treatment and patient satisfaction. J Clin Oncol 2002;20:1008–1016.
 17. Cykert S, Dilworth-Anderson P, Monroe MH, et al. Factors associated 
with decisions to undergo surgery among patients with newly diagnosed 
early-stage lung cancer. JAMA 2010;303:2368–2376.
 18. Street RL, Gordon HS, Ward MM, Krupat E, Kravitz RL. Patient partici-
pation in medical consultations—why some patients are more involved 
than others. Med Care 2005;43:960–969.
 19. Stewart MA. Effective physician–patient communication and health out-
comes: a review. CMAJ 1995;152:1423–1433.
 20. Heszen-Klemens I, Lapińska E. Doctor-patient interaction, patients’ 
health behavior and effects of treatment. Soc Sci Med 1984;19:9–18.
 21. Street RL Jr. Information-giving in medical consultations: the influence 
of patients’ communicative styles and personal characteristics. Soc Sci 
Med 1991;32:541–548.
 22. Graydon J, Galloway S, PalmerWickham S, et al. Information needs 
of women during early treatment for breast cancer. J Adv Nurs 
1997;26:59–64.
 23. Mills ME, Sullivan K. The importance of information giving for patients 
newly diagnosed with cancer: a review of the literature. J Clin Nurs 
1999;8:631–42.
 24. Comstock LM, Hooper EM, Goodwin JM, Goodwin JS. Physician behav-
iors that correlate with patient satisfaction. J Med Educ 1982;57:105–112.
 25. Ishikawa H, Takayama T, Yamazaki Y, Seki Y, Katsumata N, Aoki Y. The 
interaction between physician and patient communication behaviors in 
Japanese cancer consultations and the influence of personal and consulta-
tion characteristics. Patient Educ Couns 2002;46:277–285.
 26. Di Blasi Z, Harkness E, Ernst E, Georgiou A, Kleijnen J. Influence 
of context effects on health outcomes: a systematic review. Lancet 
2001;357:757–762.
 27. Baile WF, Aaron J. Patient–physician communication in oncology: past, 
present, and future. Curr Opin Oncol 2005;17:331–335.
 28. Zinn W. The empathic physician. Arch Intern Med 1993;153:306–12.
 29. Morse DS, Edwardsen EA, Gordon HS. Missed opportunities for 
interval empathy in lung cancer communication. Arch of Intern Med 
2008;168:1853–1858.
 30. Henoch I, Bergman B, Gustafsson M, Gaston-Johansson F, Danielson E. 
The impact of symptoms, coping capacity, and social support on quality 
of life experience over time in patients with lung cancer. J Pain Symptom 
Manage 2007;34:370–379.
 31. Sanders SL, Bantum EO, Owen JE, Thornton AA, Stanton AL. 
Supportive care needs in patients with lung cancer. Psychooncology 
2010;19:480–489.
 32. Walker MS, Zona DM, Fisher EB. Depressive symptoms after lung cancer 
surgery: their relation to coping style and social support. Psychooncology 
2006;15:684–693.
 33. Voils CI, Steffens DC, Flint EP, Bosworth HB. Social support and locus 
of control as predictors of adherence to antidepressant medication in an 
elderly population. Am J Geriatr Psychiatry 2005;13:157–165.
 34. Naylor K, Ward J, Polite BN. Interventions to improve care related to 
colorectal cancer among racial and ethnic minorities: a systematic review. 
J Gen Intern Med 2012;27:1033–1046.
 35. Lee JH, Fulp W, Wells KJ, Meade CD, Calcano E, Roetzheim R. Patient nav-
igation and time to diagnostic resolution: results for a cluster randomized 
trial evaluating the efficacy of patient navigation among patients with breast 
cancer screening abnormalities, Tampa, FL. PLoS ONE 2013;8:e74542.
 36. Schoenthaler A, Chaplin WF, Allegrante JP, et al. Provider communica-
tion effects medication adherence in hypertensive African Americans. 
Patient Educ Couns 2009;75:185–191.
 37. Epstein RM. Making communication research matter: what do patients 
notice, what do patients want, and what do patients need? Patient Educ 
Couns 2006;60:272–278.
